Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Lenalidomide prolongs EFS and OS in R/R DLBCL patients receiving palliative therapy
Key clinical point: Lenalidomide should be highly considered as a treatment option for R/R DLBCL patients receiving palliative care.
Major finding: Patients receiving lenalidomide experienced significantly longer median EFS compared with bendamustine or gemcitabine-based regimens (P = .006).
Study details: A total of 383 patients were included in the final analysis .
Disclosures: The authors did not report conflicts of interest.
Commentary
“Patients with refractory diffuse large B-cell lymphoma (DLBCL) typically have poor outcomes. Lenalidomide is a novel agent with efficacy in multiple non Hodgkin lymphoma subtypes. In this retrospective review of the Flatiron Health database, Dr. Ayers et al found that DLBCL patients receiving lenalidomide had significantly longer event free survival compared to those receiving standard chemotherapy regimens including bendamustine and gemcitabine. Overall survival of lenalidomide-treated patients was also superior to those on the other regimens. Given this data as well as its oral administration which can be easily dose-adjusted, lenalidomide is a promising agent in refractory DLBCL.”
Sarah Rutherford, MD
Assistant Professor of Medicine, Weill Cornell Medicine
Dr. Rutherford serves as a consultant for Celgene.
Ayers EC et al. Clinical Lymphoma Myeloma and Leukemia. 2020; doi.org/10.1016/j.clml.2020.05.008.